P91第二波英国SARS-CoV-2期间COVID-19患者细菌感染对发病率和死亡率的影响

S. Waring, G. Gamtkitsulashvili, S. Kumar, Y. Narayan, A. D'Souza, S. Jiwani, O. Taylor, G. Collins, K. Patrick, A. Sethuraman, S. Naik, S. Kuckreja, R. Ragatha, M. Anwar, U. Ekeowa, P. Russell
{"title":"P91第二波英国SARS-CoV-2期间COVID-19患者细菌感染对发病率和死亡率的影响","authors":"S. Waring, G. Gamtkitsulashvili, S. Kumar, Y. Narayan, A. D'Souza, S. Jiwani, O. Taylor, G. Collins, K. Patrick, A. Sethuraman, S. Naik, S. Kuckreja, R. Ragatha, M. Anwar, U. Ekeowa, P. Russell","doi":"10.1136/thorax-2021-btsabstracts.201","DOIUrl":null,"url":null,"abstract":"P91 Table 1(a) Most frequently observed bacterial species (b) Culture type positivity with relation to rates of mortality(a) Bacteria Number isolated (b) Culture Type Number of positives Number of deaths Positivity mortality Enterococcus 67 Urine 104 28 26.9% Escherichia 65 Blood 76 28 36.8% Staphylococcus 64 Skin 40 16 40% Pseudomonas 24 Sputum & BAL 33 20 60.6% Klebsiella 12 Stool 13 5 38.5% Streptococcus 12 Central venous line 8 4 50% ConclusionBacterial infection is observed far more frequently in COVID-19 patients than previously reported and adversely affects morbidity and mortality. Multiple sites of bacterial infection prolongs inpatient stay and increases mortality. Thorough culture collection should be encouraged in COVID-19 patients with biochemical evidence of bacterial infection to identify responsible pathogens and respective antimicrobial sensitivity. Given the higher mortality rates, empirical use of antibiotics in COVID-19 patients without supporting evidence of bacterial infection is strongly discouraged.ReferencesLansbury, et al. J Infect. 2020 Aug;81(2):266–2.Russell C, et al. Lancet Microbe. 2021 Jun 2. https://doi.org/10.1016/S2666-5247(21)00090-2","PeriodicalId":266318,"journal":{"name":"COVID-19: clinical features and risk","volume":"15 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"P91 Impact of bacterial infections in patients with COVID-19 on morbidity and mortality during the second UK SARS-CoV-2 wave\",\"authors\":\"S. Waring, G. Gamtkitsulashvili, S. Kumar, Y. Narayan, A. D'Souza, S. Jiwani, O. Taylor, G. Collins, K. Patrick, A. Sethuraman, S. Naik, S. Kuckreja, R. Ragatha, M. Anwar, U. Ekeowa, P. Russell\",\"doi\":\"10.1136/thorax-2021-btsabstracts.201\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"P91 Table 1(a) Most frequently observed bacterial species (b) Culture type positivity with relation to rates of mortality(a) Bacteria Number isolated (b) Culture Type Number of positives Number of deaths Positivity mortality Enterococcus 67 Urine 104 28 26.9% Escherichia 65 Blood 76 28 36.8% Staphylococcus 64 Skin 40 16 40% Pseudomonas 24 Sputum & BAL 33 20 60.6% Klebsiella 12 Stool 13 5 38.5% Streptococcus 12 Central venous line 8 4 50% ConclusionBacterial infection is observed far more frequently in COVID-19 patients than previously reported and adversely affects morbidity and mortality. Multiple sites of bacterial infection prolongs inpatient stay and increases mortality. Thorough culture collection should be encouraged in COVID-19 patients with biochemical evidence of bacterial infection to identify responsible pathogens and respective antimicrobial sensitivity. Given the higher mortality rates, empirical use of antibiotics in COVID-19 patients without supporting evidence of bacterial infection is strongly discouraged.ReferencesLansbury, et al. J Infect. 2020 Aug;81(2):266–2.Russell C, et al. Lancet Microbe. 2021 Jun 2. https://doi.org/10.1016/S2666-5247(21)00090-2\",\"PeriodicalId\":266318,\"journal\":{\"name\":\"COVID-19: clinical features and risk\",\"volume\":\"15 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"COVID-19: clinical features and risk\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/thorax-2021-btsabstracts.201\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"COVID-19: clinical features and risk","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/thorax-2021-btsabstracts.201","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

P91表1 (a)最常观察到细菌物种(b)文化类型积极与有关的死亡率(a)细菌数量孤立(b)文化类型的正面积极的死亡人数死亡67尿104 28 26.9%大肠肠球菌65血76 28 36.8%葡萄球菌64皮肤40 16 40%假单胞菌24痰& BAL 33 20 60.6%克雷伯氏菌12凳子13 5 38.5%链球菌12中央静脉8号线4 50% ConclusionBacterial感染是观察到的更多在COVID-19患者中的发病率比先前报道的要高,并对发病率和死亡率产生不利影响。多个部位的细菌感染延长了住院时间并增加了死亡率。应鼓励对有细菌感染生化证据的COVID-19患者进行彻底的培养收集,以确定负责的病原体和各自的抗菌药物敏感性。鉴于较高的死亡率,强烈不鼓励在没有细菌感染证据的情况下对COVID-19患者经验性使用抗生素。参考文献lansbury等。中国生物医学工程学报,2016,31(2):369 - 369。罗素C等人。《柳叶刀微生物》2021年6月2日。https://doi.org/10.1016/s2666 - 5247 (21) 00090 - 2
本文章由计算机程序翻译,如有差异,请以英文原文为准。
P91 Impact of bacterial infections in patients with COVID-19 on morbidity and mortality during the second UK SARS-CoV-2 wave
P91 Table 1(a) Most frequently observed bacterial species (b) Culture type positivity with relation to rates of mortality(a) Bacteria Number isolated (b) Culture Type Number of positives Number of deaths Positivity mortality Enterococcus 67 Urine 104 28 26.9% Escherichia 65 Blood 76 28 36.8% Staphylococcus 64 Skin 40 16 40% Pseudomonas 24 Sputum & BAL 33 20 60.6% Klebsiella 12 Stool 13 5 38.5% Streptococcus 12 Central venous line 8 4 50% ConclusionBacterial infection is observed far more frequently in COVID-19 patients than previously reported and adversely affects morbidity and mortality. Multiple sites of bacterial infection prolongs inpatient stay and increases mortality. Thorough culture collection should be encouraged in COVID-19 patients with biochemical evidence of bacterial infection to identify responsible pathogens and respective antimicrobial sensitivity. Given the higher mortality rates, empirical use of antibiotics in COVID-19 patients without supporting evidence of bacterial infection is strongly discouraged.ReferencesLansbury, et al. J Infect. 2020 Aug;81(2):266–2.Russell C, et al. Lancet Microbe. 2021 Jun 2. https://doi.org/10.1016/S2666-5247(21)00090-2
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信